OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
NCT Number: NCT04611568
This trial studies how well a health educational campaign works in increasing early detection of melanoma in Oregon. The health educational campaign may provide information to help people learn about the early signs of melanoma. Increased education in Oregon may decrease the number of people who die from melanoma and increase the number of melanomas that are identified at an earlier stage.
This study is active but is not currently recruiting participants.
Notify Me12 year and older
All sexes
Interventional
Not applicable
Portland, Oregon, 97239, United States
PRIMARY OBJECTIVES:
I. To measure the change in melanoma literacy in Oregon, Washington, and Utah over five years (relative to baseline) and determine if there is a statistically significant difference in literacy in Oregon (where the educational campaign occurred) as compared to the non-participating states (Washington and Utah).
II. To determine if there is an association between melanoma literacy and 1) stage at diagnosis, 2) tumor depth, 3) incidence, and 4) mortality rates in Oregon, Washington, and Utah.
III. To determine if the cost of care for melanoma in Oregon is impacted by melanoma literacy and/or tumor stage.
OUTLINE:
MEDIA CAMPAIGN: Participants view digital media strategies.
PRIMARY CARE PROVIDERS AND PROFESSIONALS: Primary care providers and professionals who see skin and potential melanomas receive online based curriculum on melanoma. Participants also complete a survey to assess knowledge and confidence before and after receiving the curriculum.
MELANOMA COMMUNITY REGISTRY VOLUNTEERS: Melanoma Community Registry volunteers in Oregon receive educational and training materials on melanoma. Participants also complete a survey before and after receiving educational material.
HIGH SCHOOL STUDENTS: High school students receive an educational lecture over 1 hour on sun-safety and early detection of melanoma practices. Participants also complete a survey before and after the educational lecture.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Receive educational and training material
Other names: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
Receive melanoma curriculum
View digital media strategies
Complete survey
Time frame: Up to completion of surveys, assessed up to 5 years
Will compare the level of knowledge and early detection of melanoma between participants in Oregon who received the educational campaign and those who did not in Washington and Utah.
Time frame: Up to 5 years
Will collect baseline and post-intervention data from Oregon State Cancer Registry (OSCaR) on melanoma diagnoses to correlate the incidence and pathologic factors with demographic and geographic factors.
Time frame: Up to 5 years
Will compare reports of cost data between those who received the health education campaign and those who did not.
Time frame: Up to completion of surveys, assessed up to 5 years
Will determine the reach of the educational campaign across Oregon using volunteer activity logs, volunteer training logs, and website usage analysis.
OHSU Knight Cancer Institute
Other
Educational Program for the Early Detection of Melanoma in Oregon
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04996823
Melanoma, Neoplasms
Tampa, Florida, United States
View Trial DetailsNCT06305247
Carcinoma, Carcinoma, Squamous Cell
Los Angeles, California, United States
View Trial DetailsNCT05470283
Melanoma, Metastatic Melanoma
Houston, Texas, United States
View Trial DetailsNCT02465060
Adenocarcinoma, Adnexal Diseases
Birmingham, Alabama, United States
View Trial Details